Dr. Robin Breyâ€™s primary research interest is neurocognitive deficits in
systemic lupus erythematous (SLE) with a focus on the role of antiphospholipid
(aPL) and anti-ribosomal P (anti-P) antibodies.
Her recent projects have
explored the association of persistently positive antibody status, ethnicity,
and cognitive dysfunction in SLE compared with a group of healthy controls.
Additionally, she has played a pivotal role in studies investigating the
mechanisms of aPL in the development of pathologically-proven ischemic brain
infarction and in cognitive decline in aging.
Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR,
Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL,
Mohr JP, deFilippi CR. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013 Mar;44(3):714-9. Arvanitakis Z,
Brey RL, Rand JH, Schneider JA, Leurgans SE, Yu L,
Buchman AS, Arfanakis K, Fleischman DA, Boyle PA, Bennett DA, Levine SR. Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study. Neuroepidemiology. 2013;40(2):73-84.
Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M,
Sampedro M, Holliday SL, Franklin C, Wallace DJ, Weisman MH, Petri M. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum. 2011 Oct;63(10):3048-57.
Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: a consensus report. Lupus. 2011 Feb;20(2):153-7.